Viridian Therapeutics, Inc.\DE short interest in 2021
In 2021, Viridian Therapeutics, Inc.\DE's disclosed short interest ran from 1.54% of shares outstanding on 15 Apr 2021 to 1.53% on 31 Dec 2021, a change of -0.01 percentage points. The year's high was 1.62% on 14 May 2021 and its low 0.56% on 15 Sep 2021, averaging 1.06% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.02 days on 14 May 2021. Full history: Viridian Therapeutics, Inc.\DE.
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 1.54% (15 Apr 2021)
- End of year
- 1.53% (31 Dec 2021)
- Change
- -0.01 pp
- High
- 1.62% (14 May 2021)
- Low
- 0.56% (15 Sep 2021)
- Average
- 1.06%
- Highest days to cover
- 11.02 (14 May 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Apr 2021 | 1.54% | 4.14 | results (8-K), 10-K filed |
| 30 Apr 2021 | 1.17% | 1.42 | |
| 14 May 2021 | 1.62% | 11.02 | results (8-K), 10-Q filed |
| 28 May 2021 | 0.98% | 2.17 | |
| 15 Jun 2021 | 1.21% | 2.35 | |
| 30 Jun 2021 | 1.12% | 1.83 | |
| 15 Jul 2021 | 1.10% | 6.80 | |
| 30 Jul 2021 | 1.04% | 10.38 | |
| 13 Aug 2021 | 0.68% | 4.33 | results (8-K), 10-Q filed |
| 31 Aug 2021 | 0.58% | 1.00 | |
| 15 Sep 2021 | 0.56% | 1.00 | |
| 29 Oct 2021 | 1.39% | 1.58 | |
| 15 Nov 2021 | 0.65% | 1.86 | results (8-K), 10-Q filed |
| 30 Nov 2021 | 0.73% | 2.21 | |
| 15 Dec 2021 | 1.06% | 2.07 | |
| 31 Dec 2021 | 1.53% | 1.86 |
See also: Viridian Therapeutics, Inc.\DE's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.